Press release
Multiple sclerosis Pipeline Analysis, 2025 by DelveInsight | Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, W
DelveInsight's, "Multiple sclerosis - Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.DelveInsight reports that the Multiple Sclerosis (MS) pipeline includes over 75 key companies actively developing more than 80 therapeutic candidates.
Multiple sclerosis Overview:
Multiple sclerosis (MS) is the most common neurological disorder affecting young adults, typically emerging between the ages of 20 and 40. The disease targets the axons in the central nervous system, which are protected by myelin, often referred to as white matter.
The relapsing-remitting form of MS (RRMS) is the most prevalent, representing about 85% of cases. RRMS is characterized by periods of symptom flare-ups-known as relapses or exacerbations-followed by phases of partial or complete remission. Less common forms of MS present differently and less predictably. In RRMS, relapses may recur and are often triggered by specific factors.
Relapses involve either the sudden worsening of existing symptoms or the emergence of new symptoms lasting at least 24 hours, typically caused by new lesions or damage in the brain.
Early MS symptoms may include:
*
Visual disturbances: blurred or double vision, or optic neuritis causing eye pain and sudden vision loss
*
Muscle weakness: particularly in the arms or legs, often accompanied by stiffness and painful spasms
*
Sensory changes: tingling, numbness, or pain in the limbs, trunk, or face
*
Coordination and balance issues: clumsiness while walking
*
Bladder dysfunction
*
Dizziness: occasional or persistent
The severity and duration of these symptoms can vary widely among individuals.
Download our report @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Multiple sclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple sclerosis Therapeutics Market.
Key Takeaways from the Multiple sclerosis Pipeline Report
DelveInsight's report on the Multiple Sclerosis (MS) pipeline highlights a dynamic landscape, with over 75 companies actively developing more than 80 therapeutic candidates.
Key regulatory updates include:
*
January 2025: The FDA issued a boxed warning for glatiramer acetate (Copaxone and its generics) due to rare but serious allergic reactions, including anaphylaxis. Patients are advised to seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling, or hives after an injection.
*
September 2024: The FDA approved a new device designed for short-term use to improve gait in MS patients with mild to moderate symptoms, providing a non-pharmacological option to aid mobility.
*
August 2024: The FDA approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab), for adults with relapsing forms of MS, aiming to increase treatment accessibility and potentially reduce costs.
Leading companies developing MS therapies include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others.
Promising MS pipeline candidates in various stages of development include IMU-838, BIIB091, IMCY-0141, NeuroVax, among several additional therapies.
Multiple sclerosis Pipeline Analysis
The Multiple sclerosis pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Multiple sclerosis Market.
*
Categorizes Multiple sclerosis therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Multiple sclerosis drugs under development based on:
*
Stage of development
*
Multiple sclerosis Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Multiple sclerosis Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Multiple sclerosis Licensing agreements
*
Funding and investment activities supporting future Multiple sclerosis market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Multiple sclerosis Emerging Drugs
*
IMU-838: Immunic Therapeutics
*
BIIB091: Biogen
*
IMCY-0141: ImCyse
*
NeuroVax: Immune Response BioPharma
Multiple sclerosis Companies
More than 75 leading companies are actively developing therapies for Multiple Sclerosis, with Immunic Therapeutics advancing a drug candidate to the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 80+ products under different phases of Multiple sclerosis clinical trials like
*
Multiple sclerosis Late stage Therapies (Phase III)
*
Multiple sclerosis Mid-stage Therapies (Phase II)
*
Multiple sclerosis Early-stage Therapies (Phase I)
*
Multiple sclerosis Pre-clinical and Multiple sclerosis Discovery stage Therapies
*
Multiple sclerosis Discontinued & Inactive Therapies
Multiple sclerosis pipeline report provides the Multiple sclerosis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Multiple sclerosis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple sclerosis Therapies and Key Multiple sclerosis Companies: Multiple sclerosis Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Multiple sclerosis Pipeline Therapeutic Assessment
- Multiple sclerosis Assessment by Product Type
- Multiple sclerosis By Stage
- Multiple sclerosis Assessment by Route of Administration
- Multiple sclerosis Assessment by Molecule Type
Download Multiple sclerosis Sample report to know in detail about the Multiple sclerosis treatment market @ Multiple sclerosis Therapeutic Assessment [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Multiple sclerosis Current Treatment Patterns
4. Multiple sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple sclerosis Late-Stage Products (Phase-III)
7. Multiple sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple sclerosis Discontinued Products
13. Multiple sclerosis Product Profiles
14. Multiple sclerosis Key Companies
15. Multiple sclerosis Key Products
16. Dormant and Discontinued Products
17. Multiple sclerosis Unmet Needs
18. Multiple sclerosis Future Perspectives
19. Multiple sclerosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Multiple sclerosis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-sclerosis-pipeline-analysis-2025-by-delveinsight-novartis-sanofi-immunic-biocad-apimeds-genentech-roche-merck-ab-science-apurano-pharmaceuticals-biogen-tiziana-life-sciences-w]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple sclerosis Pipeline Analysis, 2025 by DelveInsight | Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, W here
News-ID: 4165689 • Views: …
More Releases from ABNewswire

Myelin Regeneration in Multiple Sclerosis Clinical Trials, Companies, Therapeuti …
DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
According to DelveInsight, the Myelin Regeneration in Multiple Sclerosis pipeline…

Opioid Withdrawal Syndrome Pipeline Analysis, 2025 by DelveInsight | Chiesi Farm …
DelveInsight's, "Obstructive Sleep Apnea (OSA) Pipeline Insight, 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Obstructive Sleep Apnea (OSA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea therapeutics assessment by product type, stage, Obstructive Sleep Apnea route of administration, and Obstructive Sleep Apnea molecule type.
DelveInsight reports that the Opioid Withdrawal Syndrome pipeline…

Parainfluenza Virus Infection Pipeline Analysis and Clinical Trials Assessment, …
DelveInsight's, "Parainfluenza Virus Infection - Pipeline Insight, 2025," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Parainfluenza Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Parainfluenza Virus Infection Pipeline constitutes 5+ key companies…

Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerev …
DelveInsight's, "Parkinson's disease - Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Parkinson's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Parkinson's Disease pipeline includes over 130…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…